CXCL8 and neoplasm: The role of CXCL8 in tumor progression [8, 9] and the therapeutic benefits derived from targeting/lowering this chemokine were also demonstrated in thyroid cancer [10, 11]. In vivo experiments showed that treatment with an anti-CXCL8 neutralizing antibody abrogated the invasiveness of papillary thyroid cancer cells in mice transplanted with a human thyroid cancer cell line [11].